Methotrexate therapy for chronic noninfectious uveitis
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose To evaluate the outcomes of patients with chronic noninfectious uveitis unresponsive to conventional antiinflammatory therapy who were treated with methotrexate.Design Retrospective noncomparative interventional case series.Participants All patients with chronic noninfectious uveitis treated with methotrexate at a single institution from 1985 to 1999.Methods Charts of patients seen on the Ocular Immunology & Uveitis Service at the Massachusetts Eye & Ear Infirmary were reviewed. Patients with chronic uveitis of noninfectious origin treated with methotrexate were included in the study.Main outcome measures Control of inflammation, steroid-sparing effect, visual acuity, adverse reactions.Results A total of 160 patients met the inclusion criteria. Control of inflammation was achieved in 76.2% of patients. Steroid-sparing effect was achieved in 56% of patients. Visual acuity was maintained or improved in 90% of patients. Side effects requiring discontinuation of medication occurred in 18% of patients. Potentially serious adverse reactions occurred in only 8.1% of patients. There was neither long-term morbidity nor mortality caused by methotrexate.Conclusions Methotrexate is effective in the treatment of chronic noninfectious uveitis that fails to respond to conventional steroid treatment. It is an effective steroid-sparing immunomodulator, is a safe medication, and is well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, non-comparative retrospective case series have reported success rates ranging from 37–76% for methotrexate11–13,23 and 54–96% for mycophenolate mofetil.11,14,15,24,25”
From A Bayesian Analysis of a Randomized Clinical Trial Comparing Antimetabolite Therapies for Non-Infectious Uveitis (2017) · cites this paper as [23]
Citations
Cites
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Bloch-Michel, E., & Nussenblatt, R. B. (1987) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)74235-7 · Cited by 729
Williams, H. J., Willkens, R. F., Samuelson, C. O., Alarcón, G. S., Guttadauria, M., Yarboro, C., Polisson, R. P., Weiner, S. R., Luggen, M. E., Billingsley, L. M., et al. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280702 · Cited by 462
Glucocorticoid-Induced Osteoporosis
Baylink, D. J. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090509 · Cited by 402
GUBNER, R. S., August, S., & Ginsberg, V. (1951) · PubMed · Cited by 375
ANDERSEN, P. A., WEST, S. G., O'DELL, J. R., VIA, C. S., CLAYPOOL, R. G., & KOTZIN, B. L. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-489 · Cited by 331
THE MECHANISM OF ACTION OF METHOTREXATE
Cronstein, B. N. (1997) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70358-6 · Cited by 312
Gubner, R., August, S., & Ginsberg, V. (1951) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195102000-00009 · Cited by 308
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Research works printed but not linked: 1
- Wong, 1965, Methotrexate in the therapy of cyclitis, Trans Am Acad Ophthalmol Otolaryngol, 69, 279
Cited by
Methotrexate for Ocular Inflammatory Diseases
Gangaputra, S., Newcomb, C. W., Liesegang, T. L., Kaçmaz, R. O., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.020 · Cited by 330
Self-citationSmith, J. A., Thompson, D. J. S., Whitcup, S. M., Suhler, E., Clarke, G., Smith, S., Robinson, M., Kim, J., & Barron, K. S. (2005) · Arthritis Care & Research · doi:10.1002/art.20904 · Cited by 308
Uveitis: A Potentially Blinding Disease
Durrani, O. M., Meads, C. A., & Murray, P. I. (2004) · Ophthalmologica · doi:10.1159/000078612 · Cited by 304
Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
Ungprasert, P., Ryu, J. H., & Matteson, E. L. (2019) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.04.006 · Cited by 297
Visual loss in uveitis of childhood
de Boer, J. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.7.879 · Cited by 296
Metadata
- Authors
- Samson, C. M., Waheed, N., Baltatzis, S., & Foster, C. S.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Foster, C.Stephen
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2001-06
- Volume
- 108
- Issue
- 6
- Pages
- 1134-1139
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2142555697
- Cited by
- 250
- References
- 33
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 8 · 2023: 2 · 2022: 12 · 2021: 8 · 2020: 4 · 2019: 6 · 2018: 14 · 2017: 14 · 2016: 16 · 2015: 11 · 2014: 6 · 2013: 9 · 2012: 8
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- methotrexate, steroid-sparing therapy, immunomodulatory therapy, inflammation control, visual acuity outcomes, adverse drug reactions, drug safety
- MeSH terms
- Adolescent, Adult, Aged, Chronic Disease, Drug Evaluation, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Retrospective Studies, Safety, Uveitis, Visual Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methotrexate therapy for chronic noninfectious uveitis. https://app.cochat.ai/papers/10.1016/s0161-6420(01)00576-0
- The paper
- Samson, C. M., Waheed, N., Baltatzis, S., & Foster, C. S. (2001). Methotrexate therapy for chronic noninfectious uveitis. Ophthalmology. https://doi.org/10.1016/s0161-6420(01)00576-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.